Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment
出版年份 2016 全文链接
标题
Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment
作者
关键词
-
出版物
JOURNAL OF CLINICAL PHARMACOLOGY
Volume 56, Issue 12, Pages 1484-1499
出版商
Wiley
发表日期
2016-05-21
DOI
10.1002/jcph.765
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Osimertinib: First Global Approval
- (2016) Sarah L. Greig DRUGS
- Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial
- (2016) Chih-Jian Lih et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm
- (2016) Antonio Marchetti et al. Journal of Thoracic Oncology
- Alectinib Approved for ALK+ Lung Cancer
- (2016) Cancer Discovery
- Decision-making impact on adjuvant chemotherapy allocation in early node-negative breast cancer with a 21-gene assay: systematic review and meta-analysis
- (2015) Federico Augustovski et al. BREAST CANCER RESEARCH AND TREATMENT
- Mechanisms of lapatinib resistance in HER2-driven breast cancer
- (2015) Valentina D’Amato et al. CANCER TREATMENT REVIEWS
- Individualization of tamoxifen therapy: Much more than just CYP2D6 genotyping
- (2015) Lisette Binkhorst et al. CANCER TREATMENT REVIEWS
- Next-Generation Sequencing to Guide Clinical Trials
- (2015) L. L. Siu et al. CLINICAL CANCER RESEARCH
- Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen
- (2015) Aurelia H. M. de Vries Schultink et al. CLINICAL PHARMACOKINETICS
- Targeted therapy in her2-positive metastatic breast cancer: a review of the literature
- (2015) X. Zhu et al. Current Oncology
- Diagnostic associations of gene expression signatures in prostate cancer tissue
- (2015) Hao G. Nguyen et al. CURRENT OPINION IN UROLOGY
- Therapeutic management of ALK+nonsmall cell lung cancer patients
- (2015) Boris Duchemann et al. EUROPEAN RESPIRATORY JOURNAL
- Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic Medicine
- (2015) Amanda J. Redig et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial
- (2015) Ariel Lopez-Chavez et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31
- (2015) Karen A. Gelmon et al. JOURNAL OF CLINICAL ONCOLOGY
- Stem cell state and the epithelial-to-mesenchymal transition: Implications for cancer therapy
- (2015) Vera S. Donnenberg et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy
- (2015) Lucy Lee et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Application of Molecular Profiling in Clinical Trials for Advanced Metastatic Cancers
- (2015) S. Kummar et al. JNCI-Journal of the National Cancer Institute
- A Decision Support Framework for Genomically Informed Investigational Cancer Therapy
- (2015) Funda Meric-Bernstam et al. JNCI-Journal of the National Cancer Institute
- Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
- (2015) Christophe Le Tourneau et al. LANCET ONCOLOGY
- NCI-MATCH pairs tumor mutations with matching drugs
- (2015) Vicki Brower NATURE BIOTECHNOLOGY
- NCI-MATCH trial pushes cancer umbrella trial paradigm
- (2015) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
- (2015) David M. Hyman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oncotype DX® colon cancer assay for prediction of recurrence risk in patients with stage II and III colon cancer: A review of the evidence
- (2015) Y. Nancy You et al. SURGICAL ONCOLOGY-OXFORD
- Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy
- (2015) Anna Niezgoda et al. Biomed Research International
- Application of Molecular Profiling in Clinical Trials for Advanced Metastatic Cancers
- (2015) S. Kummar et al. JNCI-Journal of the National Cancer Institute
- A Decision Support Framework for Genomically Informed Investigational Cancer Therapy
- (2015) Funda Meric-Bernstam et al. JNCI-Journal of the National Cancer Institute
- Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options
- (2015) Hanfang Jiang et al. Therapeutic Advances in Medical Oncology
- Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet
- (2015) Grant A. McArthur Frontiers in Oncology
- Trastuzumab emtansine: mechanisms of action and drug resistance
- (2014) Mark Barok et al. BREAST CANCER RESEARCH
- Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process
- (2014) Kelly Caudle et al. CURRENT DRUG METABOLISM
- Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
- (2014) Hidemi Kawajiri et al. Expert Review of Anticancer Therapy
- Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
- (2014) Ian E Krop et al. LANCET ONCOLOGY
- Discovery and saturation analysis of cancer genes across 21 tumour types
- (2014) Michael S. Lawrence et al. NATURE
- Assessing the clinical utility of cancer genomic and proteomic data across tumor types
- (2014) Yuan Yuan et al. NATURE BIOTECHNOLOGY
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Navigating the Rapids: The Development of Regulated Next-Generation Sequencing-Based Clinical Trial Assays and Companion Diagnostics
- (2014) Saumya Pant et al. Frontiers in Oncology
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- (2013) Antonio C. Wolff et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
- (2013) J-Y Douillard et al. BRITISH JOURNAL OF CANCER
- Prospective Study of the Effect of the 21-Gene Assay on Adjuvant Clinical Decision-Making in Japanese Women With Estrogen Receptor-Positive, Node-Negative, and Node-Positive Breast Cancer
- (2013) Hideko Yamauchi et al. Clinical Breast Cancer
- CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations
- (2013) M A Province et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Clinical Implementation of Germ Line Cancer Pharmacogenetic Variants During the Next-Generation Sequencing Era
- (2013) N K Gillis et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing
- (2013) K E Caudle et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update
- (2013) M V Relling et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Afatinib: First Global Approval
- (2013) Rosselle T. Dungo et al. DRUGS
- Genomics-Driven Oncology: Framework for an Emerging Paradigm
- (2013) Levi A. Garraway JOURNAL OF CLINICAL ONCOLOGY
- Biologic Determinants of Tumor Recurrence in Stage II Colon Cancer: Validation Study of the 12-Gene Recurrence Score in Cancer and Leukemia Group B (CALGB) 9581
- (2013) Alan P. Venook et al. JOURNAL OF CLINICAL ONCOLOGY
- Validation of the 12-Gene Colon Cancer Recurrence Score in NSABP C-07 As a Predictor of Recurrence in Patients With Stage II and III Colon Cancer Treated With Fluorouracil and Leucovorin (FU/LV) and FU/LV Plus Oxaliplatin
- (2013) Greg Yothers et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Validation and Implementation of Targeted Capture and Sequencing for the Detection of Actionable Mutation, Copy Number Variation, and Gene Rearrangement in Clinical Cancer Specimens
- (2013) Colin C. Pritchard et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- (2013) Garrett M Frampton et al. NATURE BIOTECHNOLOGY
- 'Basket studies' will hold intricate data for cancer drug approvals
- (2013) Cassandra Willyard NATURE MEDICINE
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?
- (2012) Daniel Crona et al. Biomarkers in Medicine
- CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8
- (2012) M. P. Goetz et al. CLINICAL CANCER RESEARCH
- Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants
- (2012) J. M. Heuckmann et al. CLINICAL CANCER RESEARCH
- Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma
- (2012) A. M. Menzies et al. CLINICAL CANCER RESEARCH
- Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- (2012) Y. Nakamura et al. JNCI-Journal of the National Cancer Institute
- CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
- (2012) James M. Rae et al. JNCI-Journal of the National Cancer Institute
- CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- (2012) Meredith M. Regan et al. JNCI-Journal of the National Cancer Institute
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- KLC1-ALK: A Novel Fusion in Lung Cancer Identified Using a Formalin-Fixed Paraffin-Embedded Tissue Only
- (2012) Yuki Togashi et al. PLoS One
- Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement
- (2011) Hye Ryun Kim et al. CANCER
- CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
- (2011) Hiroshi Sakamoto et al. CANCER CELL
- Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing
- (2011) M V Relling et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
- (2011) Nikhil Wagle et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
- (2011) Masahiro Fukuoka et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study
- (2011) Kenneth J O'Byrne et al. LANCET ONCOLOGY
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
- (2011) Robert Pirker et al. LANCET ONCOLOGY
- BRAFMutations in Hairy-Cell Leukemia
- (2011) Enrico Tiacci et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing
- (2011) Nikhil Wagle et al. Cancer Discovery
- Dose-Dependent Association between UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Low Doses Also Increase Risk
- (2010) Z.-Y. Hu et al. CLINICAL CANCER RESEARCH
- Prospective Multicenter Study of the Impact of the 21-Gene Recurrence Score Assay on Medical Oncologist and Patient Adjuvant Breast Cancer Treatment Selection
- (2010) Shelly S. Lo et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The HERNATA Study
- (2010) Michael Andersson et al. JOURNAL OF CLINICAL ONCOLOGY
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer
- (2009) K. Takeuchi et al. CLINICAL CANCER RESEARCH
- I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
- (2009) AD Barker et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples
- (2009) Laura E. MacConaill et al. PLoS One
- Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
- (2008) P MEDINA et al. CLINICAL THERAPEUTICS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started